摘要
目的运用循证医学方法对索拉非尼治疗晚期肝癌的临床疗效进行系统评价。方法计算机检索"万方数据资源系统"、"中国生物医学文献服务系统"、"中国期刊全文数据库"、"中文科技期刊数据库",在评价文献质量的基础上纳入了符合标准的随机对照临床试验7项,对其进行异质性分析,然后采用随机效应模型合并治疗有效率、疾病控制率和毒副反应发生率进行Meta分析。结果索拉非尼治疗晚期肝癌的有效率(OR=1.84;95%CI:1.26～2.70)和疾病控制率(OR=3.03;95%CI:2.07～4.44)与对照组比较差异均有统计学意义。结论索拉非尼可提高晚期肝癌的治疗有效率和疾病控制率。
Objective To assess the effectiveness of sorafenib in the treatment of advanced hepatocellular carci- noma by evidence-based medicine methods. Methods The articles were retrieved from Wanfang Data, VIP informa- tion, CNKI and Sinomed. After strict quality evaluation of the articles,7 clinical randomized controlled trials were in- ternalized according to our accepting criteria. The heterogeneity test among the 7 trials were did, and then the re- sponse rate, the disease control rate and the rates of toxicities were consolidated based on randomized effects model for Meta-analysis. Results The response rate （OR=1.84; 95% CI： 1.26-2.70） and the disease rate （OR= 3.03; 95% CI： 2.07-4.44） of sorafenib in the treatment of advanced hepatocellular carcinoma were significantly different from those of the control group. Conclusion Sorafenib has positive effects in the treatment of advanced hepatocellular carcinoma by improving the response rate and the disease control rate.
出处
《肿瘤基础与临床》
2013年第1期38-42,共5页
journal of basic and clinical oncology
